Mexiletine for the Treatment of Focal Dystonia
Blepharospasm, Dystonia, Spasm
About this trial
This is an interventional treatment trial for Blepharospasm focused on measuring Blepharospasm, Writer's Cramp, Muscle Spindle Afferents, Sodium Channels, Sensorimotor Integration, Focal Dystonia
Eligibility Criteria
INCLUSION CRITERIA: Patients with focal dystonia, specifically writer's cramp and blepharospasm, will be eligible for study. Patients will need medical clearance, specifically, cardiac clearance, by their primary care physician. This will include an EKG within the past 12 months and no history of underlying cardiac disease. EXCLUSION CRITERIA: Patients with any of the following conditions will be excluded from the study: structural brain lesions, identifiable etiology for dystonia (such as stroke, trauma, Parkinson's Disease, Wilson's Disease, or peripheral neuropathy), contractures or fixed joint deformities, current or past use of neuroleptics, seizures, prior neurosurgery, or co-existent neurologic or general medical illness, including history of cardiovascular disease or peptic ulcer disease and pregnant or breast-feeding women. Patients who are taking or have taken mexiletine will be excluded as well.
Sites / Locations
- National Institute of Neurological Disorders and Stroke (NINDS)